title: Persistent adenovirus-mediated thymidine kinase gene expression in ovarian cancer cells increases cell killing efficacy over time.
abstract: Adenovirus (ADV)-mediated gene therapy with the thymidine kinase (TK) gene under control of the Rous sarcoma virus (RSV) promotor followed by the administration of acyclovir has been established in vitro for the treatment of ovarian cancer cells and has been used as the basis for intraperitoneal phase I clinical trials. It is unclear how long a significant degree of transgene translation can be expected after adenovirus-mediated TK transduction, where the transcriptional complex is localized in the nucleus in an episomal fashion and thus without stable integration. The possible interaction of acyclovir pretreatment with subsequent ADV-RSV-TK transduction also remains to be elucidated. Transgene expression and cell killing efficacy were analysed based on multiplicity of infection (MOI) and MTT assay. Anti-TK-antibody 1397 was used for immunocytochemistry and Western blot analysis of TK expression. After transduction with ADV-RSV-TK at an MOI of 66, TK translation increased strongly in MDH 2774 and OVCAR-3 cell lines during the initial 48 hours. Virtually constant expression of the TK transgene was observed by Western blot during eight days. Cell killing efficacy was increased by repeated daily administrations of acyclovir. Pretreatment with acyclovir did not result in significantly increased cell killing efficacy. No negative effect of acyclovir on ADV-RSV-TK transduction was observed. The at least week-long expression of the TK transgene with persistently increasing efficacy of cell killing after ADV-mediated tumor cell transduction provide a realistic basis for the development of multicycle ADV-mediated TK gene therapy approaches in the treatment of ovarian cancer. Continuous i.v. acyclovir treatment or daily oral acyclovir-prodrug therapy might simplify the substrate regimen for the TK gene.
authors.affiliation: HELIOS Medical Center, Aue, Germany. dirk.kieback@helios-kliniken.de
authors.forename: D G
authors.initials: DG
authors.lastname: Kieback
authors.forename: B
authors.initials: B
authors.lastname: Delvoux
authors.forename: A
authors.initials: A
authors.lastname: Romano
authors.forename: S
authors.initials: S
authors.lastname: Ollig
authors.forename: D C
authors.initials: DC
authors.lastname: Fischer
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000493:pharmacokinetics; D000256:Adenoviridae / Q000235:genetics; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000628:therapy*; D011401:Promoter Regions, Genetic; D052736:Rous sarcoma virus / Q000235:genetics; D013937:Thymidine Kinase / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D014161:Transduction, Genetic; D019076:Transgenes
chemical_list: D000998:Antiviral Agents; D013937:Thymidine Kinase; D000212:Acyclovir